HELX - ETF AI Analysis
Top Page
Franklin Genomic Advancements ETF (HELX)
Rating:61Neutral
Price Target:―
Positive Factors
Focused Genomics Exposure
The fund concentrates on genomic and advanced health care companies, giving investors targeted access to a specialized growth area.
Several Strong Top Holdings
Some of the largest positions, such as Krystal Biotech, United Therapeutics, Ligand Pharma, and AstraZeneca, have shown strong year-to-date performance, helping support the ETF’s returns.
Reasonable Fund Size
With tens of millions in assets under management, the ETF is large enough to be established but still focused on its niche strategy.
Negative Factors
High Sector Concentration
Nearly all assets are in health care, so the fund is heavily exposed to swings in one industry.
Weak Recent Performance
The ETF has delivered negative results so far this year and over the last three months, showing recent performance has been weak.
Several Lagging Key Holdings
Some major positions like Natera, Guardant Health, Insmed, Adaptive Biotechnologies, and Medpace have posted weak year-to-date performance, which can drag on overall returns.
HELX vs. SPDR S&P 500 ETF (SPY)
AUM21.72M
RegionGlobal
Expense Ratio0.50%
Beta0.87
IssuerFranklin
Inception DateFeb 25, 2020
Dividend Yield0.43%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume345
30 Day Avg. Volume972
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.18Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering60
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HELX Summary
Franklin Genomic Advancements ETF (HELX) is a health care–focused fund that invests in companies working with genetic research and DNA-based medicine. It follows the theme of genomic advancements rather than a traditional market index, aiming to benefit from progress in areas like genetic testing and personalized treatments. The fund holds both specialists and big names such as AstraZeneca, giving investors a way to spread their money across many genomic innovators instead of picking single stocks. A key risk is that it’s heavily concentrated in biotech and can be very volatile, going up or down sharply with news and market sentiment.
How much will it cost me?The Franklin Genomic Advancements ETF (HELX) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche in genomic advancements, which requires more research and expertise compared to passively managed funds.
What would affect this ETF?The Franklin Genomic Advancements ETF (HELX) could benefit from growing interest in personalized medicine and advancements in genetic research, as well as increased healthcare spending globally. However, it may face challenges from regulatory hurdles in biotechnology, potential setbacks in clinical trials, and broader economic pressures that could impact funding for innovation. Its heavy focus on healthcare and genomic advancements makes it sensitive to both breakthroughs and disruptions in this niche sector.
HELX Top 10 Holdings
HELX is a pure play on genomic medicine, and its fate is tied closely to a handful of high‑octane biotech names. United Therapeutics and Krystal Biotech have been doing the heavy lifting lately, with steady-to-rising share prices that help offset turbulence elsewhere. Ligand Pharma has also been a quiet engine of gains. On the flip side, Natera, Guardant Health, and Adaptive Biotechnologies have been lagging, acting like a headwind for the fund. With most holdings in health care and a global mix led by U.S. names, this ETF is highly concentrated in cutting-edge, higher-risk innovators.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Natera | 6.66% | $1.46M | $28.88B | 33.60% | 73 Outperform | |
| Guardant Health | 6.36% | $1.39M | $11.66B | 84.41% | 61 Neutral | |
| Krystal Biotech | 5.51% | $1.21M | $8.02B | 60.70% | 80 Outperform | |
| United Therapeutics | 4.35% | $952.54K | $24.86B | 90.88% | 79 Outperform | |
| Ligand Pharma | 4.19% | $917.35K | $4.61B | 122.07% | 60 Neutral | |
| BridgeBio Pharma | 4.15% | $908.55K | $14.21B | 107.63% | 59 Neutral | |
| Insmed | 3.69% | $806.63K | $29.18B | 94.65% | 43 Neutral | |
| AstraZeneca | 3.17% | $692.85K | $292.69B | 32.74% | 80 Outperform | |
| Adaptive Biotechnologies | 3.13% | $685.56K | $2.18B | 82.88% | 53 Neutral | |
| Vertex Pharmaceuticals | 2.79% | $611.32K | $109.45B | -14.20% | 78 Outperform |
HELX Technical Analysis
Positive
―
Price Trends
33.32
Positive
34.90
Negative
33.37
Positive
Market Momentum
0.03
Positive
53.49
Neutral
50.88
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HELX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.77, equal to the 50-day MA of 33.32, and equal to the 200-day MA of 33.37, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 53.49 is Neutral, neither overbought nor oversold. The STOCH value of 50.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HELX.
HELX Peer Comparison
Comparison Results
Performance Comparison
HELX
Franklin Genomic Advancements ETF
33.96
6.79
24.99%
FFND
Future Fund Active ETF
―
―
―
CSNR
Cohen & Steers Natural Resources Active ETF
―
―
―
IQM
Franklin Intelligent Machines ETF
―
―
―
HECO
SPDR Galaxy Hedged Digital Asset Ecosystem ETF
―
―
―
TEKY
Lazard Next Gen Technologies ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents